Senti Biosciences (NASDAQ:SNTI) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Senti Biosciences (NASDAQ:SNTI) in a report released on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.00 price objective on the stock.

SNTI has been the topic of several other reports. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of Senti Biosciences in a research report on Friday, August 8th. Wall Street Zen upgraded Senti Biosciences from a “sell” rating to a “hold” rating in a research report on Monday, August 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.67.

Senti Biosciences Stock Up 23.8%

Shares of Senti Biosciences stock opened at $2.08 on Tuesday. The stock’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $2.38. Senti Biosciences has a 52 week low of $1.26 and a 52 week high of $16.94. The company has a market capitalization of $54.41 million, a price-to-earnings ratio of -0.23 and a beta of 2.04.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.02. The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $1.30 million. On average, equities analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.

Institutional Investors Weigh In On Senti Biosciences

Several large investors have recently added to or reduced their stakes in SNTI. Geode Capital Management LLC increased its stake in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the last quarter. Armistice Capital LLC bought a new stake in Senti Biosciences during the second quarter worth approximately $1,883,000. Heights Capital Management Inc. bought a new stake in Senti Biosciences during the first quarter worth approximately $2,520,000. Finally, Nantahala Capital Management LLC bought a new stake in Senti Biosciences during the first quarter worth approximately $2,984,000. 25.73% of the stock is owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.